At the (pre)seed stage, not much has changed. For companies scaling into their Series As and Bs, I would say have two plans. One for more aggressive growth assuming mission aligned, patient capital is available (which, for now at least, still seems to be the case). But also, it's smart to have a more conservative cockroach plan should we enter a new zone of short term pain. In the long run though, I may be naive, but I'm not too worried. Truly breakthrough ideas with organic, explosive growth will always find a way ;)